ReWalk Exoskeleton Gains Aetna Coverage, Now Accessible Through Three Major Medicare Advantage Plans

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

Aetna approves Medicare Advantage coverage for ReWalk exoskeleton, expanding access to three major insurers serving 16 million beneficiaries and marking progress for wearable robotic technology reimbursement.

ReWalk Exoskeleton Gains Aetna Coverage, Now Accessible Through Three Major Medicare Advantage Plans

Lifeward announced that Aetna has approved Medicare Advantage coverage for its ReWalk Personal Exoskeleton, marking a significant expansion of insurer support for the FDA-approved wearable technology. The approval brings the total number of major Medicare Advantage carriers covering the device to three, alongside existing coverage from Humana and UnitedHealthcare.

The three insurers collectively serve approximately 16 million Medicare Advantage beneficiaries, substantially broadening patient access to the exoskeleton system designed for individuals with spinal cord injuries. This expanded coverage represents a key milestone for reimbursement of wearable robotic technology within the Medicare Advantage market, historically a challenge for emerging medical devices seeking mainstream adoption.

The addition of Aetna coverage reflects growing recognition of the ReWalk system's clinical value and potential to improve mobility and quality of life for eligible patients. The sequential approvals across multiple major carriers suggest potential for continued expansion of coverage policies within the Medicare Advantage landscape.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 17

Related Coverage

GlobeNewswire Inc.

BioCardia Gets FDA Nod on Dual Pathways for Helix Catheter System

BioCardia secured FDA alignment on two regulatory routes for its Helix transendocardial delivery catheter, with the agency backing simultaneous approval with CardiAMP cell therapy.

BCDA
Benzinga

Stryker Bolsters Vascular Portfolio with Amplitude Acquisition

Stryker completes acquisition of Boston-based Amplitude Vascular Systems, adding next-generation intravascular lithotripsy technology to peripheral vascular offerings.

SYK
GlobeNewswire Inc.

Glucotrack Advances Implantable Glucose Monitor With FDA Clinical Study Approval

Glucotrack submits IDE application for FDA clinical trial of implantable continuous glucose monitoring technology, marking major regulatory milestone for diabetes care innovation.

GCTK
GlobeNewswire Inc.

Healthcare Analytics Market to Surge Past $380B by 2034 Amid AI Boom

Healthcare analytics market projected to grow 24% annually from $56B (2025) to $390B (2034), driven by EHR adoption, AI integration, and value-based care models.

MSFTORCLORCLpD
The Motley Fool

UnitedHealth Stock Surges 37% After Q1 Beat, Stronger Margin Recovery

$UNH rallied 36.9% in April on Q1 earnings beat and raised guidance, with improving medical loss ratios signaling healthcare cost recovery.

UNH
Benzinga

IceCure's ProSense Cryoablation Gains Momentum as Q1 Revenue Surges 30%

IceCure Medical showcased ProSense® cryoablation at breast surgeons conference, reporting 30%+ Q1 revenue growth as adoption accelerates.

ICCM